ECSP099239A - Determinadas amidas sustituidas, método de elaboración y método de uso de las mismas - Google Patents

Determinadas amidas sustituidas, método de elaboración y método de uso de las mismas

Info

Publication number
ECSP099239A
ECSP099239A EC2009009239A ECSP099239A ECSP099239A EC SP099239 A ECSP099239 A EC SP099239A EC 2009009239 A EC2009009239 A EC 2009009239A EC SP099239 A ECSP099239 A EC SP099239A EC SP099239 A ECSP099239 A EC SP099239A
Authority
EC
Ecuador
Prior art keywords
amidas
elaboration
same
certain substituted
methods
Prior art date
Application number
EC2009009239A
Other languages
English (en)
Inventor
Kevin Currie
Scott Mitchell
Jianjun Xu
Peter A Blomgren
Seung H Lee
Aaron C Schmitt
Jeffrey E Kropf
James W Darrow
Original Assignee
Cgi Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cgi Pharmaceuticals Inc filed Critical Cgi Pharmaceuticals Inc
Publication of ECSP099239A publication Critical patent/ECSP099239A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Al menos una entidad química seleccionada entre los compuestos de Fórmula 1; y sales aceptables para uso farmacéutico, quelatos, complejos no covalentes, prodrogas y mezclas de los mismos. Composiciones farmacéuticas que comprenden al menos una entidad química de la invención, junto con al menos un vehículo aceptable para uso farmacéutico seleccionado entre vehículos, coadyuvantes y excipientes. Métodos para tratar pacientes que sufren de ciertas enfermedades que responden a la inhibición de la actividad de Btk y/o la actividad de las células B y métodos para determinar la presencia de Btk en una muestra.
EC2009009239A 2006-09-11 2009-04-07 Determinadas amidas sustituidas, método de elaboración y método de uso de las mismas ECSP099239A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84395906P 2006-09-11 2006-09-11

Publications (1)

Publication Number Publication Date
ECSP099239A true ECSP099239A (es) 2009-07-31

Family

ID=38951317

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009239A ECSP099239A (es) 2006-09-11 2009-04-07 Determinadas amidas sustituidas, método de elaboración y método de uso de las mismas

Country Status (23)

Country Link
US (1) US8058446B2 (es)
EP (1) EP2081923B1 (es)
JP (1) JP5295961B2 (es)
KR (1) KR101442585B1 (es)
CN (1) CN101679361A (es)
AR (1) AR063706A1 (es)
AU (1) AU2007296559B2 (es)
BR (1) BRPI0716918A2 (es)
CA (2) CA2941688A1 (es)
CL (1) CL2007002640A1 (es)
CO (1) CO6160313A2 (es)
CR (1) CR10710A (es)
EC (1) ECSP099239A (es)
ES (1) ES2576478T3 (es)
IL (1) IL197230A0 (es)
MA (1) MA30782B1 (es)
MX (1) MX2009002649A (es)
NO (1) NO20091424L (es)
PE (1) PE20080839A1 (es)
RU (1) RU2009113693A (es)
TW (1) TW200829579A (es)
WO (1) WO2008033854A1 (es)
ZA (1) ZA200901633B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838523B2 (en) * 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
EP2205564B1 (en) * 2007-10-23 2014-07-30 F. Hoffmann-La Roche AG Novel kinase inhibitors
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
JP5627574B2 (ja) * 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
WO2009156284A1 (en) 2008-06-24 2009-12-30 F. Hoffmann-La Roche Ag Novel substituted pyridin-2-ones and pyridazin-3-ones
AU2009265813B2 (en) * 2008-07-02 2014-04-10 F. Hoffmann-La Roche Ag Novel phenylpyrazinones as kinase inhibitors
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN110818724B (zh) * 2010-05-07 2020-11-13 吉利德康涅狄格有限公司 吡啶酮和氮杂吡啶酮化合物及使用方法
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
KR20140096100A (ko) 2011-11-03 2014-08-04 에프. 호프만-라 로슈 아게 이환 피페라진 화합물
BR112014010439A2 (pt) 2011-11-03 2017-04-18 F Hoffmann - La Roche Ag compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica
RU2622391C2 (ru) 2011-11-03 2017-06-15 Ф. Хоффманн-Ля Рош Аг Соединения 8-фторфталазин-1(2н)-она в качестве ингибиторов тирозинкиназы брутона
AU2012382373A1 (en) * 2012-06-12 2014-12-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
JP6348492B2 (ja) 2012-08-10 2018-06-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤としてのヘテロ芳香族化合物
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
SG11201506764WA (en) 2013-04-25 2015-09-29 Beigene Ltd Fused heterocyclic compounds as protein kinase inhibitors
CN104177338B (zh) * 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
WO2015000949A1 (en) 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone amide compounds
MD4684B1 (ro) 2013-07-30 2020-03-31 Gilead Connecticut INc. Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
ES2822285T3 (es) 2013-07-30 2021-04-30 Kronos Bio Inc Polimorfo de inhibidores de SYK
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
AU2014337064B2 (en) 2013-10-18 2019-03-14 Celgene Quanticel Research, Inc. Bromodomain inhibitors
EP3077384B1 (en) 2013-12-05 2017-09-06 F. Hoffmann-La Roche AG Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
MX2016007346A (es) * 2013-12-09 2016-09-13 Abbvie Inc Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio.
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
KR102003754B1 (ko) 2014-07-03 2019-07-25 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
WO2016139361A1 (en) * 2015-03-05 2016-09-09 Boehringer Ingelheim International Gmbh New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2016358100B2 (en) 2015-11-19 2021-05-27 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201726623A (zh) 2015-12-17 2017-08-01 英塞特公司 作為免疫調節劑之雜環化合物
TWI850624B (zh) 2015-12-22 2024-08-01 美商英塞特公司 作為免疫調節劑之雜環化合物
BR112018069530B1 (pt) 2016-02-29 2021-02-17 F. Hoffmann-La Roche Ag composições de forma de dosagem que compreendem um inibidor da tirosina quinase de bruton
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3472167T3 (da) 2016-06-20 2022-09-05 Incyte Corp Heterocykliske forbindelser som immunomodulatorer
NZ749997A (en) 2016-07-05 2022-11-25 Beigene Ltd Combination of a pd-l antagonist and a raf inhibitor for treating cancer
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
KR102604975B1 (ko) 2016-08-16 2023-11-24 베이진 스위찰랜드 게엠베하 (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로 [1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도
EP3500299B1 (en) 2016-08-19 2023-12-13 BeiGene Switzerland GmbH Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
JP2019529419A (ja) 2016-09-19 2019-10-17 エムイーアイ ファーマ，インク． 併用療法
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
ES2929193T3 (es) 2016-12-22 2022-11-25 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de la internalización de PD-L1
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzooxazole derivatives as immunomodulators
WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
WO2018175863A1 (en) 2017-03-24 2018-09-27 Genentech, Inc. Methods of treating autoimmune and inflammatory diseases
KR102757960B1 (ko) 2017-06-26 2025-01-22 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
CN110997677A (zh) 2017-08-12 2020-04-10 百济神州有限公司 具有改进的双重选择性的Btk抑制剂
US11384082B2 (en) 2017-08-25 2022-07-12 Kronos Bio, Inc. Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
EP3492454A1 (en) * 2017-11-30 2019-06-05 Step Pharma S.A.S. Compounds
US11505547B2 (en) 2017-11-30 2022-11-22 Step Pharma S.A.S. Compounds
US11655246B2 (en) 2017-11-30 2023-05-23 Step Pharma S.A.S. Aminothiazole compounds as inhibitors of CTPS1
RS64055B1 (sr) 2018-03-30 2023-04-28 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
EP4219492B1 (en) 2018-05-11 2024-11-27 Incyte Corporation Heterocyclic compounds as immunomodulators
PL3870574T3 (pl) 2018-10-23 2023-05-02 Step Pharma S.A.S. Pochodne aminopirymidyny/pirazyny jako inhibitory CTPS1
US11339168B2 (en) 2019-02-22 2022-05-24 Kronos Bio, Inc. Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors
US20220249491A1 (en) 2019-06-10 2022-08-11 Beigene Switzerland Gmbh Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
JP7665593B2 (ja) 2019-08-09 2025-04-21 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
EP4037773A1 (en) 2019-09-30 2022-08-10 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
EP4240739A1 (en) 2020-11-06 2023-09-13 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
JP2002535318A (ja) * 1999-01-22 2002-10-22 アムジエン・インコーポレーテツド キナーゼ阻害薬
US7405295B2 (en) * 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
EP1812442A2 (en) * 2004-11-10 2007-08-01 CGI Pharmaceuticals, Inc. Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity
EP1831168B1 (en) 2004-12-16 2014-07-02 Vertex Pharmaceuticals Inc. Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases.
MX2007011041A (es) * 2005-03-10 2008-02-22 Cgi Pharmaceuticals Inc Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
JP2009506123A (ja) * 2005-08-29 2009-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド 非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン
US7838523B2 (en) * 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
EP2270200A3 (en) * 2006-09-11 2011-07-13 CGI Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
AR063707A1 (es) * 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras

Also Published As

Publication number Publication date
JP5295961B2 (ja) 2013-09-18
AU2007296559B2 (en) 2013-01-17
BRPI0716918A2 (pt) 2013-11-05
ZA200901633B (en) 2009-12-30
RU2009113693A (ru) 2010-10-20
MA30782B1 (fr) 2009-10-01
CA2661654C (en) 2016-10-11
KR101442585B1 (ko) 2014-10-02
JP2010504287A (ja) 2010-02-12
US20080139557A1 (en) 2008-06-12
CO6160313A2 (es) 2010-05-20
NO20091424L (no) 2009-06-10
AU2007296559A1 (en) 2008-03-20
PE20080839A1 (es) 2008-08-23
CN101679361A (zh) 2010-03-24
CL2007002640A1 (es) 2008-06-20
CR10710A (es) 2009-07-14
AR063706A1 (es) 2009-02-11
KR20090074762A (ko) 2009-07-07
EP2081923A1 (en) 2009-07-29
CA2661654A1 (en) 2008-03-20
WO2008033854A1 (en) 2008-03-20
EP2081923B1 (en) 2016-03-16
IL197230A0 (en) 2009-12-24
US8058446B2 (en) 2011-11-15
MX2009002649A (es) 2009-03-26
ES2576478T3 (es) 2016-07-07
TW200829579A (en) 2008-07-16
CA2941688A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
ECSP099239A (es) Determinadas amidas sustituidas, método de elaboración y método de uso de las mismas
ECSP099238A (es) Amidas sustituidas, método de elaboración y método de uso de las mismas
CO6382177A2 (es) Determinadas imidazol[1,2-a]pirazin-8-ilaminas, metodo de preparacion y metodo de uso de las mismas
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
MX2011006091A (es) Inhibidores de imidazopirazina syk.
CR6824A (es) Derivados de arilmetilamina para uso como inhibidores de triptasa
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
UY29633A1 (es) Derivados de oxindol
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
ECSP088246A (es) Nuevos derivados de benzotiazolona
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
ATE507204T1 (de) Isoindolin-verbindungen und deren verwendungen
GT200600496A (es) Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea.
CY1112085T1 (el) Παραγωγα κυκλοεξυλαμινης ισοκινολονης ως αναστολεις της rho-κινασης
UY27222A1 (es) Pirazolopirimidinas como agentes terapéuticos
ECSP088296A (es) Compuestos terapéuticos
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
BRPI0518993A2 (pt) composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
UY29370A1 (es) Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação